FREE Account Opening + No Clearing Fees
Loading...
June 16, 2017 - June 20, 2017

Eris Lifesciences IPO Review & Recommendations

, Dilip Davda, , and have given "Apply" recommendation to Eris Lifesciences IPO. recommend to "Avoid" the IPO.

Eris Lifesciences IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 5 0 0 1 0
% 83.33 0.00 0.00 16.67 0.00

Eris Lifesciences IPO Analysis By Brokers/Analysts

Reviewer Recommendation Past Reviews
Apply
Avoid
Dilip Davda Apply
Apply
Apply
Apply

Eris Lifesciences IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Eris Lifesciences IPO is 45. Their analysis recommends May subscribe for the IPO.

Reviewer Rating Score Rating
Capital Market 45 May subscribe

Eris Lifesciences IPO Review by Dilip Davda (Apply)

[Dilip Davda]  Investors may consider investment for medium to long term in this niche player having better penetration. Read detail review...

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.